Executive interview – Silence Therapeutics

Executive interview – Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines in the increasingly high-profile sector of RNA therapeutics, using the body’s natural mechanism of RNA interference to inhibit the expression of disease. On the back of two recent strategic deals, on 25 March 2020 the company announced a major collaboration with AstraZeneca to develop novel drugs for cardiovascular, renal, metabolic and respiratory diseases. Here to talk through the details of the AstraZeneca deal and equity investment, strategic initiatives and forthcoming milestones for Silence Therapeutics are Dr Rob Quinn, CFO and Dr John Strafford, Head of Business Development.

Silence Therapeutics (SLN) has a portfolio of siRNA drugs in early-stage testing. SLN124 for iron overload is the most advanced and is entering the clinic in Q120. SLN360 is being developed for cardiovascular disease and an IND is planned for H220.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free